Evidence map›Paper›PMID 29786513›Full record

ArticleSocial science & medicine (1982)2018

Randomized clinical trials and personalized medicine: A commentary on deaton and cartwright.

Nicholas J Schork

Abstract readComment
In one paragraph

Article in Social science & medicine (1982), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Exploring human biology with N-of-1 clinical trials.Cambridge prisms. Precision medicine · 2023
    Article
  7. Can we Reconcile Evidence-based Medicine with Personalized Medicine: Poised on a Cusp!Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022
    Article
  8. Article
  9. Does Modulation of an Epigenetic Clock Define a Geroprotector?Advances in geriatric medicine and research · 2022
    Article
  10. Article
  11. Strategies for Testing Intervention Matching Schemes in Cancer.Clinical pharmacology and therapeutics · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. What is Evidence-Based Functional Medicine in the 21st Century?Integrative medicine (Encinitas, Calif.) · 2019
    Article
  16. Artificial Intelligence and Personalized Medicine.Cancer treatment and research · 2019
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Nicholas J SchorkThe Translational Genomics Research Institute (TGen), Phoenix, AZ, United States; The City of Hope/TGen IMPACT Center, Duarte, CA, United States; The J. Craig Venter Institute, La Jolla, CA, United States; The University of California, San Diego, La Jolla, CA, United States. Electronic address: NSchork@jcvi.org.

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Integrative Resource to Develop Translational Strategies to Promote LongevityU24AG051129 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON, EVANS, DANIEL SPENCER · 2015 to 2019
$5.3M
NCATS NIH HHS UL1 TR001442NIA NIH HHS U24 AG051129
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Precision MedicineRandomized Controlled Trials as Topic

Identifiers

PMID29786513
PMCPMC6388397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.